Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years

References

• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• XuWColletJPShapiroSNegative impacts of unreported COPD exacerbations on health-related quality of life at 1 yearEur Respir J20103551022103019897555
   PubMed Web of Science ®Google Scholar
• LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741216452599
   PubMed Web of Science ®Google Scholar
• Chronic respiratory diseases Available from: http://www.who.int/gard/publications/chronic_respiratory_diseases.pdfAccessed August 10, 2012
   Google Scholar
• Chronic obstructive pulmonary disease (COPD) fact sheet2013 Available from: http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html#note_10Accessed August 10, 2012
   Google Scholar
• Centers for Disease Control and Prevention (CDC)Deaths from chronic obstructive pulmonary disease – United States, 2000–2005MMWR Morb Mortal Wkly Rep200857451229123219008792
   PubMedGoogle Scholar
• FosterTSMillerJDMartonJPCaloyerasJPRussellMWMenzinJAssessment of the economic burden of COPD in the US: a review and synthesis of the literatureCOPD20063421121817361502
   PubMedGoogle Scholar
• DisseBSpeckGARomingerKLWitekTJJrHammerRTiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung diseaseLife Sci1999646–745746410069510
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20052CD00287615846642
   PubMed Web of Science ®Google Scholar
• KestenSCasaburiRKukafkaDCooperCBImprovement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patientsInt J Chron Obstruct Pulmon Dis20083112713618488436
   PubMedGoogle Scholar
• Tudorza™ Pressair™ [package insert]Forest Pharmaceuticals, Inc.St Louis, MO2012
   Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarcia GilECaractaCFEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease IncGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdfAccessed August 21, 2012
   Google Scholar
• PriceDGrayAGaleRCost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPDRespir Med2011105111635164721764277
   PubMed Web of Science ®Google Scholar
• Rutten-van MolkenMLeeTAEconomic modeling in chronic obstructive pulmonary diseaseProc Am Thorac Soc20063763063416963546
   PubMedGoogle Scholar
• QuanjerPHTammelingGJCotesJEPedersenOFPeslinRYernaultJCLung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory SocietyEur Respir J Suppl1993165408499054
   PubMedGoogle Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2013840542324043936
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• HoogendoornMRutten-van MolkenMPHoogenveenRTAlMJFeenstraTLDeveloping and applying a stochastic dynamic population model for chronic obstructive pulmonary diseaseValue Health20111481039104722152172
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• RennardSIScanlonPDFergusonGTACCORD COPD II: A randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig20133312893904
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten-van MolkenMPMonzBUFitzGeraldJMProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countriesValue Health200581324615841892
   PubMed Web of Science ®Google Scholar
• AriasEUnited States life tables, 2007Natl Vital Stat Rep201159916022070012
   PubMedGoogle Scholar
• Rutten-van MölkenMPMHOostenbrinkJBTashkinDPBurkhartDMonzBUDoes quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?Chest200613041117112817035446
   PubMed Web of Science ®Google Scholar
• EarnshawSRWilsonMRDalalAACost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDRespir Med20091031122119010652
   PubMed Web of Science ®Google Scholar
• PickardASYangYLeeTAComparison of health-related quality of life measures in chronic obstructive pulmonary diseaseHealth Qual Life Outcomes201192621501522
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireResp Med199185Suppl B2531
   PubMed Web of Science ®Google Scholar
• StarkieHJBriggsAHChambersMGJonesPPredicting EQ-5D values using the SGRQValue Health201114235436021402304
   PubMed Web of Science ®Google Scholar
• ObaYCost-effectiveness of salmeterol, fluticasone, and combination therapy for COPDAm J Manag Care200915422623219355795
   PubMed Web of Science ®Google Scholar
• SunSXMarynchenkoMBanerjeeRCost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium mono-therapy for treating severe-to-very severe COPDJ Med Econ201114680581521992217
   PubMedGoogle Scholar
• YuAPYangHWuEQSetyawanJMocarskiMBlumSIncremental third-party costs associated with COPD exacerbations: a retrospective claims analysisJ Med Econ201114331532321500975
   PubMedGoogle Scholar
• Rutten-van MolkenMPOostenbrinkJBMiravitllesMMonzBUModelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in SpainEur J Health Econ20078212313517370096
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor StatisticsConsumer Price Index Detailed Report: Data for December 2011 Available from: http://www.bls.gov/cpi/cpid1112.pdfAccessed August 21, 2012
   Google Scholar
• The AMCP format for formulary submissions version 3.0J Manag Care Pharm2010161 Suppl A13020044848
   PubMed Web of Science ®Google Scholar
• BriggsAHGlickHALozano-OrtegaGIs treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH studyEur Respir J201035353253919717476
   PubMed Web of Science ®Google Scholar
• SinDDGolmohammadiKJacobsPCost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severityAm J Med2004116532533114984818
   PubMed Web of Science ®Google Scholar
• PatersonCLanganCEMcKaigGAAssessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D)Qual Life Res20009552152711190007
   PubMed Web of Science ®Google Scholar
• SpencerSJonesPWGLOBE Study GroupTime course of recovery of health status following an infective exacerbation of chronic bronchitisThorax200358758959312832673
   PubMed Web of Science ®Google Scholar
• Red Book^®OnlineAmerican Academy of Pediatrics Available from: http://aapredbook.aappublications.org/Accessed Aug 21, 2012
   Google Scholar